ChartMill assigns a fundamental rating of 3 / 10 to LOXO.
ChartMill assigns a valuation rating of 0 / 10 to Loxo Oncology Inc. (LOXO). This can be considered as Overvalued.
Loxo Oncology Inc. (LOXO) has a profitability rating of 4 / 10.
The financial health rating of Loxo Oncology Inc. (LOXO) is 6 / 10.
The Earnings per Share (EPS) of Loxo Oncology Inc. (LOXO) is expected to grow by 57.63% in the next year.